On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

NetworkNewsBreaks – BriaCell Therapeutics Corp. (TSX.V: BCT) (OTCQB: BCTXF) Details Proposed Financing Deals Valued at Up to $4.8M

Company: BriaCell Therapeutics Corp. (BCTXF)
Category: News

Immuno-oncology focused biotechnology company BriaCell Therapeutics Corp. (TSX.V: BCT) (OTCQB: BCTXF) recently announced plans to enter into a securities purchase agreement of convertible notes with a leading group of biotech-focused institutional and family office funds for an investment of $800,000. Under the terms of the proposed agreement, the note offering will consist of a five percent unsecured convertible note of BriaCell in the principal amount of $800,000 which will be convertible at the option of the holder into common shares of BriaCell at a fixed conversion price of C$0.10 per common share. The offering will also include one common share purchase warrant, which will be valid for 36 months following the date of closing of the offering and will be exercisable for one common share at an exercise price of C$0.14. Concurrently, BriaCell also intends to complete a non-brokered private placement of units of the company at a price of $0.10 per unit for aggregate gross proceeds of up to C$4 million. Briacell intends to use the proceeds from these offerings to finance its phase IIa clinical trial and its pursuit of other research opportunities, as well as for working capital and general corporate purposes.

To view the full press release, visit http://nnw.fm/jo7ZW

About BriaCell

BriaCell is an immuno-oncology focused biotechnology company developing a targeted and safe approach to the management of cancer. Immunotherapy has come to the forefront in the fight against cancer, harnessing the body’s own immune system in recognizing and selectively destroying cancer cells while sparing normal ones. Immunotherapy, in addition to generally being more targeted and less toxic than commonly used types of chemotherapy, is also thought to be a potent approach with the potential to prevent cancer recurrence. For more information, visit the company’s website at www.BriaCell.com

More from NetworkNewsBreaks

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217